LEIPZIG, GERMANY--(MARKET WIRE)--Feb 12, 2009 -- BIOTECTID GmbH, a German biotechnology company specialized in the development and production of innovative new diagnostics, today announced that the European Patent Office has decided to grant a European patent for the new diagnostic EP1645 used in the in vivo analysis of distribution patterns of human CD4 presenting cell populations.
“This means the achievement of another important milestone in the history of BIOTECTID GmbH,” the CEO of the company, Dr. Ullrich Pigla, said. “This European patent enables Biotectid to plan on a long-term basis and to advance the clinical trials and the market entry for our portfolio products steadily. The Patent Office already told us that during the time for filing an appeal no oppositions to the patent were made. Now we have valid national rights in more than 20 member states of the European patent treaty.”
EP 1645 is a fragment of a monoclonal antibody which binds selectively to the CD4 molecule on the surface of specific inflammatory cells. One of the areas of indication is the control and optimization of the use of biopharmaceuticals in the treatment of rheumatoid arthritis.
In addition, a further clinical trial performed ex vivo reveals other very interesting opportunities for the imaging localization of high-risk arteriosclerosis plaques (HRP’s). “We expect further clinical results already in 2009; we are sure that we have a very promising new indication line here,” Pigla completed.
About BIOTECTID:
BIOTECTID GmbH is a privately held company which was founded in 1999 as a spin-off of the Universities of Leipzig and Halle with the aim of making visible chronic sources of inflammation by means of imaging procedures and localizing them objectively. The company undertakes research in the field of immunology and develops biopharmaceuticals for molecular imaging. After starting up in 2000 with five employees, its own laboratories were initially set up in Leipzig. The company, which has now moved to the Leipzig BioCity, has its own certified GMP facility, as well as laboratories with highly modern equipment. The company is integrated into a powerful network of renowned partners from the fields of research and development, science and business, and has built up a fast growing patent portfolio.
Contact: Dr. Ullrich Pigla BIOTECTID GmbH Deutscher Platz 5c 04103 Leipzig Germany Tel.: +49 341 256673-30 Fax: +49 341 256673-40 E-Mail: info@biotectid.de
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
Contact: Source: BIOTECTID GmbH
